Antiviral Activity of Hederasaponin B from *Hedera helix* against Enterovirus 71 Subgenotypes C3 and C4a

JaeHyoung Song 1,3, Sang-Gu Yeo 1,2, Eun-Hye Hong 3, Bo-Ra Lee 3, Jin-Won Kim 1, JeongHoon Kim 4, HyeonGun Jeong 3, YongSoo Kwon 3, HyunPyo Kim 3, SangWon Lee 1, Jae-Hak Park 1,5,6 and Hyun-Jeong Ko 3,5,6

1Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951,
2Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742,
3College of Pharmacy, Kangwon National University, Chunchon 200-701,
4Ahn-Gook Pharmaceutical Co., LTD, Seoul 150-953, Republic of Korea

Abstract

Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The antiviral activity of hederasaponin B from *Hedera helix* against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of *Hedera helix* containing hederasaponin B showed significant antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis. These results suggest that hederasaponin B and *Hedera helix* extract containing hederasaponin B can be novel drug candidates with broad-spectrum antiviral activity against various subgenotypes of EV71.

Key Words: Enterovirus 71, Antiviral activity, Hederasaponin B, *Hedera helix*, Hand foot and mouth disease
Hedera helix (English ivy, Common ivy) is an evergreen dioecious woody liana, one of the 15 species of the genus Hedera, Araliaceae family. The dry extract of Hedera helix is currently known to act as an anti-inflammatory (Suleyman et al., 2003; Gepdiremen et al., 2005), anti-bacterial, mucolytic and anti-spasmodic agent (Trute et al., 1997; Sieben et al., 2009). Also, Hedera helix extract has been claimed to exhibit in vitro bronchodilatatory effect on cell cultures (Trute et al., 1997; Sieben et al., 2009), and the pharmaceutical manufacturers declare the beneficial effect of ivy-based remedies in the treatment of cough symptoms during the course of acute and chronic bronchitis. However, to date, no detailed study has been carried out to assess the antiviral activity of Hedera helix against EV71.

In the current study, we reported a novel antiviral activity of 30% EtOH extract of Hedera helix against EV71 C3 and EV71 C4a, and conducted a bioassay-guided isolation and identification of an active compound from Hedera helix against EV71 C3 and EV71 C4a. The antiviral activity of hederasaponin B and the extract and fractionates of Hedera helix against EV71 C3 and EV71 C4a is promising and urgently need to be evaluated in vivo for its potential capacity as the therapeutics of HFMD, since the 30% EtOH extract of Hedera helix is a very safe medicine currently used for the treatment of bronchitis in children.

MATERIALS AND METHODS

Viruses and cell lines

EV71 C3 and EV71 C4a were obtained from the division of vaccine research in Korea Centers for Disease Control and Prevention (KCDC), and propagated in African green monkey kidney (vero) cells at 37°C. Vero cells were maintained in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS) and 0.01% antibiotic-antimycotic solution. Antibiotic-antimycotic solution, trypsin-EDTA, FBS, and MEM were supplied by Gibco BRL (Invitrogen Life Technologies, Karlsruhe, Germany). The tissue culture plates were purchased from Falcon (BD Biosciences, San Jose, CA, USA). Sulforhodamine B (SRB) was purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of reagent grade.

Fractionation and isolation

For preparation of materials, 30% EtOH extract of Hedera helix was obtained from the Sampoong Corporation (Korea) in May 2011. 30% EtOH extract (500 g) was suspended in water and then partitioned with EtOAc and n-BuOH, successively. Each soluble fraction was evaporated in vacuo to yield the residues of EtOAc (23 g), and n-BuOH (150 g) extracts, respectively. n-BuOH soluble fraction (100 g) was column chromatographed on a Diaion HP-20 (500 g, 10×50 cm) using stepwise-gradient with MeOH: H₂O (0:100, 20:80, 40:60, 60:40, 80:20, 100:0; each 1,000 ml) to afford 6 fractions. Each extract and fraction were tested for SRB-based cytotoxicity and antiviral activity against EV71 C3 and C4a. For further purification, the active fraction was subjected to ODS column chromatography (300g, YMC-Gel ODS-A, 150 μm, 5×50 cm) using isocratic elution with MeOH:H₂O (70:30) to give a pure compound. The purified compound was identified as hederasaponin B by direct comparison with the authentic compound.

Antiviral activity assay

Assays of antiviral activity was evaluated by the SRB method using CPE reduction, recently reported (Choi et al., 2009). One day before infection, vero cells were seeded onto a 96-well culture plate at a concentration of 2×10⁴ cells/well. Next day, medium was removed and then washed with 1×PBS. Subsequently, 0.09 ml of the diluted virus suspension containing 50% cell culture infective dose (CCID₅₀) of the virus stock was added to produce appropriate CPE within 48h after infection, followed by the addition of 0.01 ml of medium supplemented with FBS containing an appropriate concentration of the compounds were added. The antiviral activity of each test material was determined with a 5-fold diluted concentration ranging from 0.4 to 50 μg/ml. Four wells were used as virus controls (virus-infected non-compound-treated cells) while four wells were used as cell controls (non-infected non-compound-treated cells). The culture plates were incubated at 37°C in 5% CO₂ for 2 days until appropriate CPE was achieved. Subsequently, the 96-well plates were washed once with 1× PBS, and 100 μL of cold (-20°C) 70% acetone was added on each well and left standing for 30 min at -20°C. After the removal of 70% acetone, the plates were dried in a dry oven for 30 min, followed by the addition of 100 μl of 0.4% (w/v) SRB in 1% acetic acid solution to each well, and left standing at room temperature for 30 min. SRB was then removed, and the plates were washed 5 times with 1% acetic acid before oven-drying. The plates were dried in a dry oven. After drying for 1 day, the morphology of the cells to observation the effect of compounds on EV71 C3 and EV71 C4a-induced CPE were observed under microscope at 0.4×10 magnification (Axiovert 10; Zeiss, Wetzlar, Germany), and images were recorded. Bound SRB was then solubilized with 100 μl of 10 mM unbuffered Tris-base solution, and the plates were left on a table for 30 min. The absorbance was then read at 540 nm by using a VERSAmax microplate reader (Molecular Devices, Palo Alto, CA, USA) with a reference absorbance at 620 nm. The results were then transformed into percentage of the controls, and the percent protection achieved by the test CFS in the EV71-infected cells was calculated using the following formula: [(OD)EV71(OD)EV71]+[(OD)CFS(OD)EV71]×100 (expressed in %), where (OD)EV71 is the optical density measured with a given CFS in EV71-infected cells; (OD)EV71 is the optical density measured for the control untreated EV71-infected cells; and (OD)CFS is the optical density measured for control untreated mock-infected cells. Antiviral activity was presented as % of control. Ribavirin and DMSO were used for positive and negative control, respectively.

Cytotoxicity assay

We seeded that vero cells onto a 96-well culture plate at a concentration of 2×10⁴ cells/well. Next day, medium was removed and then washed with phosphate buffered saline (PBS). The 96-well plates were treated to compounds in maintenance medium for 48 h at 37°C, in parallel with the virus-infected cell cultures. For each compounds, 3 wells were used as controls (non-compound-treated cells). After 48 h of incubation, cytotoxicity was evaluated by SRB assay as previously described (Lin et al., 1999). Cytotoxicity was presented as % of control.

Western blot analysis

Vero cells were plated onto 6-well culture plates at a den-
Infection of 5×10^5 cells/well 24 h before infection with EV71 C3 and EV71 C4a. EV71 C3 and EV71 C4a infected cells were treated with hederasaponin B and ribavirin at a concentration 50 μg/ml for 48 h for detection of viral VP2 protein. Mock-infected cells treated with 0.1% DMSO and EV71 infected cells treated with 0.1% DMSO was used as controls. Cells were lysed in ice-cold RIPA lysis buffer containing 50 mM Tris-HCl pH7.4, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1% SDS, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 1 mM PMSF, 5 mM sodium fluoride and 5 mM sodium orthovanadate. The preparation of sample protein (30 μg) boiled for 10 min at 100°C and separated in 12% acrylamide gels run at 100 V for 1 h (for detection of VP1). The SeeBlue®Plus2 prestained protein ladder (Invitrogen) was used as a molecular weight standard. The gels were transferred to a nitrocellulose membrane using the Invitrogen iBlot® Gel Transfer Device (Invitrogen, Carlsbad, CA) at 20 V for 7 min.

For detection of VP2, membranes were blocked with 5% skim milk (Difco) dissolved in phosphate buffered saline-Tween 20 (PBST) overnight at 4°C on a shaker. The blots were washed three times with PBST before being incubated with primary mouse anti-enterovirus 71 monoclonal antibody (Millipore) dissolved in 5% skim milk at a dilution of 1:1,000. The blots were incubated with primary antibodies at room temperature on a shaker. The blots were then washed three times with PBST for 10 min each time. This was followed by incubation with the secondary antibodies polyclonal goat anti-mouse IgG (H+L)-HRP (GenDEPOT) for 1 h at room temperature on shaker. Dilution of secondary antibody was done in 5% skim milk at a ratio of 1:5,000. Membranes were then rinsed three times with PBST for 10 min each time. Membranes were developed by the enhanced chemiluminescence (ECL) method using West-Q chemiluminescent substrate (GenDEPOT).

**RESULTS**

**Antiviral activity of 30% EtOH extract of Hedera helix against EV71 C3 and EV71 C4a**

During the screening of antiviral activity of several medical plant extracts against EV71, we found that 30% ETOH extract of *Hedera helix*, which was widely used in clinic for the treatment of cough symptoms, also possessed significant antiviral activity against EV71 C3 (Table 1) and C4a (Table 2). To find the active antiviral compounds in 30% EtOH extract of *Hedera helix*, the extract which was further fractionated into EtOAc, n-BuOH, CHCl3, and Hexane fraction, and we found that the

---

Table 1. Antiviral activity of the extract and fractions of *Hedera helix* against EV71 C3

| Test material                        | CC50 a | EC50 b | TI c  |
|--------------------------------------|--------|--------|-------|
| Hedera helix 30% EtOH extract        | >50    | 6.58 ± 0.11 | 7.59 |
| 100% H2O                             | >50    | ND d   | -     |
| 20% MeOH                             | >50    | 25.23 ± 4.93 | 1.98 |
| 40% MeOH                             | >50    | 7.92 ± 1.44 | 6.31 |
| 60% MeOH                             | >50    | 2.75 ± 1.05 | 18.18|
| 80% MeOH                             | >50    | 38.22 ± 4.13 | 1.31 |
| 100% MeOH                            | 31.03  | ND d   | -     |

Results are presented as the mean EC50 values ± SD obtained from three independent experiments carried out in triplicate.  
^a Concentration required to reduce cell growth by 50% (μg/ml).  
^b Concentration required to inhibit virus-induced CPE by 50% (μg/ml).  
^c Therapeutic index=CC50/EC50.  
^d Not determined.

Table 2. Antiviral activity of the extract and fractions of *Hedera helix* against EV71 C4a

| Test material                        | CC50 a | EC50 b | TI c  |
|--------------------------------------|--------|--------|-------|
| Hedera helix 30% EtOH extract        | >50    | 22.00 ± 2.06 | 4.55 |
| 100% H2O                             | >50    | ND d   | -     |
| 20% MeOH                             | >50    | ND d   | -     |
| 40% MeOH                             | >50    | 43.12 ± 1.91 | 1.16 |
| 60% MeOH                             | >50    | 47.10 ± 5.16 | 1.06 |
| 80% MeOH                             | >50    | ND d   | -     |
| 100% MeOH                            | 31.03  | ND d   | -     |

Results are presented as the mean EC50 values ± SD obtained from three independent experiments carried out in triplicate.  
^a Concentration required to reduce cell growth by 50% (μg/ml).  
^b Concentration required to inhibit virus-induced CPE by 50% (μg/ml).  
^c Therapeutic index=CC50/EC50.  
^d Not determined.
antiviral activity was highly retained in n-BuOH fraction (data not shown). Thus, we decided to separate the n-BuOH soluble fraction using a Diaion HP-20 column and obtained 6 fractions after stepwise-gradient with MeOH:H₂O. Each fraction was tested for SRB-based cytotoxicity and antiviral activity against EV71 C3 (Table 1) and C4a (Table 2), and we found that the 40% and 60% of MeOH fractions showed significant antiviral activity. After further purification, we identified hederasaponin B as a major compound in the 40% and 60% of MeOH fractions (data not shown).

**Table 3. Antiviral activity of hederasaponin B isolated from Hedera helix against EV71 C3 and C4a**

| Compound | EV71 C3 | EV71 C4a |
|----------|---------|---------|
|          | CC₅₀ a  | EC₅₀ b  | Ti c  | CC₅₀ a  | EC₅₀ b  | Ti c  |
| Hederasaponin B | >50     | 24.77 ± 12.56 | 2.02 | >50     | 41.77 ± 0.76 | 1.18 |
| Ribavirin | >50     | ND d    | -    | >50     | ND d    | -    |

Results are presented as the mean EC₅₀ values ± S.D obtained from three independent experiments carried out in triplicate.

aConcentration required to reduce cell growth by 50% (µg/ml).
bConcentration required to inhibit virus-induced CPE by 50% (µg/ml).
cTherapeutic index=CC₅₀/EC₅₀.
dNot determined.

**Fig. 1.** The effect of hederasaponin B on Enterovirus 71 (EV71) C3-induced cytopathic effect. The virus-infected vero cells were treated with ribavirin or 50 µg/ml hederasaponin B. After, cell viability was evaluated by sulforhodamine B (SRB) assay, and the morphology of cells was photographed using a microscope. (A) Non-infected cells, (B) Non-infected cells treated with hederasaponin B, (C) Non-infected cells treated with ribavirin, (D) EV71 C3-infected cells, (E) EV71 C3-infected cells treated with hederasaponin B, (F) EV71 C3-infected cells treated with ribavirin.

Hederasaponin B affects viral VP2 protein synthesis

Viral VP2 proteins syntheses were compared between drug-treated and untreated infected cells. As shown in Fig. 3, when cells were infected with virus and cultured in the absence of drugs until processed for western blot, virus VP2 protein could be detected in the untreated cells. The size of EV71 VP2 protein has been determined to be 34 kDa and α-Tubulin was used as a loading control in the experiment as well as to ensure that hederasaponin B used in this study did not af-
fect the synthesis and expression of host cellular proteins. The western blot analysis also showed that the viral VP2 protein expression was decreased dramatically by hederasaponin B (50 μg/ml) at 48 h after infection by EV71 C3 and EV71 C4a (Fig. 3B). However, ribavirin used as a positive control did not show cytotoxicity as well as antiviral activity in vitro and in western blot analysis, which is consistent with the previous reports by Choi et al. (2009). Collectively, these results suggested that hederasaponin B possessed antiviral activity against EV71 C3 and C4a by inhibiting viral protein expression, and thus could be considered as an antiviral drug candidate for the treatment of HFMD.

**DISSCUSSION**

The current antiviral drug armamentarium comprises of almost 40 compounds that have been officially approved for clinical use including 19 drugs for treating human immunodeficiency virus (HIV) infection, 3 drugs for treating hepatitis B virus (HBV) infection, 7 drugs for treating herpes simplex virus (HSV) infection and varicella-zoster virus (VZV) infection, 2 drugs for treating respiratory syncytial virus (RSV) infection and hepatitis C virus (HCV) infection, 5 drugs for treating cytomegalovirus (CMV) infection and 4 drugs for treating influenza virus infection. However, to date, there is no approved antiviral drug for the treatment of enterovirus infections (Park et al., 2012).

Pleconaril is a potent anti-viral inhibitor of enteroviruses that is under evaluation for the treatment of diseases associated with picornavirus infections (Pevear et al., 1999). Pleconaril exerts its activity on capsid function by integrating with high affinity and specificity in the hydrophobic pocket of the virion. In 2007, Schering-Plough completed a phase II double-blind, placebo-controlled trial to study the effects of pleconaril nasal spray on common cold symptoms (De Palma et al., 2008), but the US Food and Drug Administration has not approved pleconaril because of concerns of emergence of viral resistance and side effects in patients (Fleischer and Laessig, 2003). The relevance of pleconaril resistance was demonstrated in a study by Pevear et al. (1999). Other candidates having an antiviral effect against EV71 include WIN54954, SCH48973, rupintrivir, raoulic acid, and punicalagin. In addition, antiviral activity of betulin, betulinic acid, betulonic acid, chebulagic acid isolated from the fruits of *Terminalia chebula*, and that of matrine isolated from the root of Chinese Sophora herb plants has been studied against enterovirus. Ribavirin has also been used to treat various DNA and RNA virus infections, although acquired resistance to it has been demonstrated in various virus populations and in some patients (Graci and Cameron, 2006).

Further, we and others could not observe significant antiviral activity of ribavirin against EV71 in vero cells. Therefore, broad-spectrum antiviral compounds should be developed.
against various genogroups of enteroviruses in the future.

The present study describes the cytotoxicity and antiviral activity of hederasaponin B. Hederasaponin B was shown to exhibit anti-viral activity against EV71 C3 and EV71 C4a by reducing the formation of a visible CPE. In addition, the inhibitory effects of hederasaponin B and ribavirin against EV71 were analyzed by western blot assay. The expression of EV71 C3 and C4a VP proteins was inhibited in the presence of 50 µg/ml of hederasaponin B. However, ribavirin did not show any inhibitory effect against EV71 infection. These results suggest that hederasaponin B could be a broad-spectrum antiviral compound that is effective against various EV71 subgenotypes. In addition, 30% EtOH extract of Hedera helix, which has been widely used for the treatment of acute and chronic obstructive pulmonary bronchitis due to its secretolytic and bronchiolytic effects in adults and children, also has a significant anti-viral activity against EV71 C3 and C4a, thereby suggesting that it can be developed as an anti-viral drug for EV71 infection. We also found that 40% and 60% MeOH fractions from 30% EtOH extract of Hedera helix also have significant anti-viral effects against EV71 C3 and C4a; and especially, hederasaponin B, one of the major compounds of the 40% and 60% MeOH fractions showed a significant anti-EV71 activity.

In conclusion, hederasaponin B was shown to be effective against EV71. Also, anti-EV71 activity analysis with EV71 subgenotypes C3 and C4a did not reveal a subgenotype-specific activity pattern. Further studies will be required to explore the detailed antiviral mechanism of action of hederasaponin B. We will carry out research focusing on suppression of enterovirus replication by hederasaponin B because hederasaponin B is well known to be belonged to triterpenoid saponins (Han et al., 2013) and it has been demonstrated that triterpenoid saponins inhibit viral nucleotide synthesis against herpes simplex virus type-1 in previous studies (Simoés et al., 1999).

ACKNOWLEDGEMENTS

This work was supported by a grant from R&D project (2013-NG48001-00) at Korea National Institute of Health.

REFERENCES

Brown, B. A., Oberste, M. S., Alexander, J. P. Jr., Kennett, M. L. and Pallansch, M. A. (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J. Virol. 73, 9969-9975.

Cardosa, M. J., Perera, D., Brown, B. A., Cheon, D., Chan, H. M., Chan, K. P., Cho, H. and McMinn, P. (2003) Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 9, 461-468.

Chan, Y. F., Sam, I. C. and AbuBakar, S. (2010) Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect. Genet. Evol. 10, 404-412.

Chang, L. Y., Lin, T. Y., Huang, Y. C., Tsao, K. C., Shih, S. R., Kuo, M. L., Ning, H. C., Hoult, J. R. and Raman, A. (1999) Sulphorhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J. Ethnopharmacol. 66, 141-150.

McMinn, P. C. (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91-107.

Park, K. S., Choi, Y. J. and Park, J. S. (2012) Enterovirus infection in Korean children and anti-enteroviral potential candidate agents. Korean J. Pediatr. 55, 359-366.

Pevear, D. C., Tull, T. M., Seipel, M. E. and Groarke, J. M. (1999) Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109-2115.

Poyry, T., Kinnunen, L., Hyytiä, T., Brown, B., Hörsnell, C., Hovi, T. and Stanway, G. (1996) Genetic and phylogenetic clustering of enteroviruses. J. Gen. Virol. 77, 1699-1717.

Sieben, A., Prenner, L., Sorkalla, T., Wolf, A., Jakobs, D., Runkel, F. and Haberlein, H. (2009) Sulphorhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J. Ethnopharmacol. 66, 141-150.

Simoés, C. M., Amoros, M. and Girle, L. (1999) Mechanism of antiviral activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109-2115.

Suleyman, H., Mshvildadze, V., Gepdiremen, A. and Elias, R. (2005) Alpha-hederin, but not hederacoside C and hederagenin from Hedera helix affects the binding behavior, dynamics, and regulation of beta 2-adrenergic receptors. Biochemistry 44, 3477-3482.

Suleyman, H., Mshvildadze, V., Gepdiremen, A. and Elias, R. (2003) Acute and chronic antiinflammatory profile of the ivy plant, Hedera helix, in rats. Phytomedicine 10, 370-374.

Trute, A., Gross, J., Mutschler, E. and Nahrstedt, A. (1997) In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med. 63, 125-129.

Wang, S. M., Lei, H. Y., Huang, K. J., Wu, J. M., Wang, J. R., Yu, C. K., Su, I. J. and Liu, C. C. (2003) Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J. Infect. Dis. 188, 564-570.

Zhang, Y., Wang, J., Guo, W., Wang, H., Zhu, S., Wang, D., Bai, R., Li, X., Yan, D., Wang, H., Zhang, Y., Zhu, Z., Tan, X., An, H., Xu, A. and Xu, W. (2011) Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the Central Plain of China. PloS One 6, e28795.